Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

Quintero-Aldana, G.; Jorge, Mónica; Grande, Carlos; Salgado, Mercedes; Gallardo, Elena; Varela, S.; López, Cuauhtémoc Romero; Villanueva, M.J.; Fernández, Ana; Álvarez, Elena; González, P.; Castellanos, Jorge; Casal, J.; López, Rafael; Balea, Begoña Campos

doi:10.1007/s00280-015-2839-z

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, 70–80% of these patients with lymph node metastases will relapse and die of their disease [ 30 ]. Chemotherapy including 5-FU and docetaxel in postoperative adjuvant treatment has been shown to prolong survival and improve a high quality of life [ 31 , 32 ]. Apatinib is a novel receptor tyrosine kinase inhibitor which selectively targeting the intracellular ATP-binding site of vascular endothelial growth factor receptor 2 (VEGFR-2).…”

Section: Resultsmentioning

confidence: 99%

Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer

Zhai

et al. 2017

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundGastric cancer (GC) is among the most commonly cancer occurred in Asian, especially in China. With its high heterogeneity and few of validated drug targets, GC remains to be one of the most under explored areas of precision medicine. In this study, we aimed to establish an in vivo patient-derived xenograft (PDX) model based on zebrafish (Danio rerio) embryos, allowing for a rapid analysis of the angiogenic and invasive potentials, as well as a fast drug sensitivity testing.MethodsTwo human gastric cancer cell lines (AGS and SGC-7901) were xenografted into zebrafish embryos, their sensitivity to 5-FU were tested both in vitro and in vivo. Fourteen human primary cells from gastric cancer tissue were xenografted into zebrafish embryos, their proliferating, angiogenic and metastatic activities were evaluated in vivo. Sensitivity to 5-FU, docetaxel, and apatinib were also tested on primary samples from four patients.ResultsSGC-7901 showed higher sensitivity to 5-FU than AGS both in vitro (6.3 ± 0.9 μM vs.10.5 ± 1.8 μM) and in vivo. Nine out of fourteen patient samples were successfully transplanted in zebrafish embryos and all showed proliferating, angiogenic and metastatic potentials in the living embryos. Four cases showed varied sensitivity to the selected three chemotherapeutic drugs.ConclusionsOur zebrafish PDX (zPDX) model is a preclinically reliable in vivo model for GC. The zPDX model is also a promising platform for the translational research and personalized treatment on GC.Electronic supplementary materialThe online version of this article (10.1186/s13046-017-0631-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer

Zhai

et al. 2017

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Chemotherapy was the standard of care for patients with relatively advanced gastric cancer and thanks to the introduction of new adjuvant chemotherapy regimens, overall survival (OS) among patients with gastric cancer has increased significantly during the past few years. [1][2][3] However, since gastric cancer was usually asymptomatic in early stages, researchers found it difficult to stratify and treat those patients. 4 The lack of a reliable standard to distinguish those really at high risk has made it hard for us to identify patients who would benefit from adjuvant chemotherapy when considering OS.…”

Section: Introductionmentioning

confidence: 99%

C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer

Líu

et al. 2018

OncoImmunology

View full text Add to dashboard Cite

Immune molecules, which have been found to be important in tumor microenvironment, seem prospective in tumor therapy, but they are still not effective enough to use in clinical practice. C-C motif chemokine 22 (CCL22) exists in various malignancies and correlates with migration of regulatory T cells, but its clinical significance in gastric cancer is still unclear. In this study, a combined data set of 466 patients with gastric cancer after surgical resection, comprised of a discovery (n = 319) and a validation data set (n = 147), was enrolled. CCL22 expression was assessed by immunohistochemical staining and we evaluated prognostic values of CCL22 staining and clinical outcomes with use of Kaplan-Meier curve and Multivariate Cox regression analysis. Positive CCL22 expression predicted adverse overall survival independent of traditional pathological grade. Multivariate analysis defined CCL22 and TNM stage as two independent prognostic factors for overall survival. Besides, in patients with TNM stage II/III disease, the rate of overall survival was higher among patients with CCL22-positive tumors who were treated with 5-fluorouracil based adjuvant chemotherapy than that among those who were not ( = 0.012, < 0.001 and < 0.001, in discovery, validation and combined data set). But for these with CCL22-negative tumors, whether to undergo adjuvant chemotherapy showed no statistical significance ( = 0.595, = 0.085 and P = 0.252, respectively). To conclude, CCL22 was identified as an independent adverse prognostic immunobiomarker for patients with gastric cancer after surgery, which is associated with tumor-infiltrating immunocytes and could be incorporated into TNM staging system to redefine a high-risk subgroup who were more likely to benefit from 5-fluorouracil based adjuvant chemotherapy.

show abstract

“… 43 The combined use of cisplatin, fluorouracil and docetaxel significantly prolonged the maintenance of the Karnofsky performance status and presented with better results in terms of the appetite and weight-loss analyses in advanced gastric or gastroesophageal cancer treatment, notably in the study by Ajani et al 44 In Europe and in USA, cisplatin and fluorouracil-based chemotherapy regimens with three drugs, including docetaxel or epirubicin, are widely applied, first-line chemotherapy combination regimens for treating advanced EGJA. 45 …”

Section: Discussionmentioning

confidence: 99%

A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma

Song

Xie

et al. 2017

Exp Mol Med

View full text Add to dashboard Cite

The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA). Randomized controlled trials (RCTs) related to chemotherapy regimens based on cisplatin and fluorouracil for EGJA were included from the PubMed, EMBASE and Cochrane Library electronic databases (from inception to June 2016). Direct and indirect evidence were combined to calculate the pooled odds ratio (OR) and its 95% confidence interval (95% CI) as well as to draw the surface under the cumulative ranking (SUCRA) curves. This NMA finally enrolled ten eligible RCTs with the following five regimens: cisplatin plus fluorouracil (cisplatin+fluorouracil), cisplatin+fluorouracil-based chemotherapy (cisplatin+fluorouracil+docetaxel/epirubicin/irinotecan), fluorouracil-based chemotherapy (fluorouracil+docetaxel/doxorubicin/methotrexate/irinotecan), cisplatin-based chemotherapy (cisplatin+docetaxel/epirubicin/irinotecan/capecitabine/s-1) and other drug-based chemotherapy (docetaxel/irinotecan/capecitabine). These results revealed that compared with a cisplatin+ fluorouracil-based chemotherapy regimen, the fluorouracil-based chemotherapy regimen had a lower overall response rate (ORR) and partial response (PR) for EGJA patients (ORR: OR=0.43, 95% CI=0.22–0.86; PR: OR=0.46, 95% CI=0.23–0.91). Cluster analyses suggested that the cisplatin+fluorouracil-based chemotherapy regimen had the best short-term efficacy for EGJA in terms of the complete response (CR), PR, ORR, stable disease (SD) and progression disease (PD). Our results indicated that cisplatin+fluorouracil-based chemotherapy regimens may have the best short-term efficacy in the treatment of EGJA.

show abstract

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

Abstract: Biweekly administration of docetaxel and cisplatin in advanced gastric cancer has a manageable toxicity profile and shows a promising antitumour activity as a first-line therapy.

Cited by 6 publications

References 26 publications

Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer

Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer

C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer

A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma

Contact Info

Product

Resources

About